Anaptysbio Inc (ANAB) 13F Investor Activity Report (Q2 2026)

ANAB ranks #2822 out of 37696 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

ANAB is a top-conviction position for EcoR1 Capital, LLC — at 25.9% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

Farther Finance Advisors, LLC has added to its ANAB position for two straight quarters, increasing it by $482.5K to reach $504.3K today.

MassMutual Private Wealth & Trust, FSB has trimmed its ANAB position for two straight quarters, cutting it by $1.9K while still holding $603.0.

ANAB is down 4.3% today, but institutions show net buying of $272.0M this quarter — a divergence between today's price move and the underlying institutional flow.

ANAB reported a net loss of $26.8M over the trailing twelve months.

• Not yet profitable — net loss of $26.8M over the trailing twelve months
• Revenue grew 107.7% year over year
• Net income improved year over year, from -$140.6M to -$26.8M
• Generated $19.7M in positive operating cash flow
• Current ratio of 9.07x — enough short-term assets to cover short-term liabilities
• Liabilities run x equity — a highly leveraged balance sheet worth noting